Photo: Shannon Fagan/Getty Images
AcuityMD, which offers a health data tool for the medical technology industry, has secured $80 million in Series C funding, bringing its total raise to more than $160 million and its valuation to $955 million.
Existing investor StepStone Group led the round, with participation from Redpoint Ventures, Benchmark, ICONIQ and Atreides Management.
WHAT IT DOES
Boston-based AcuityMD offers a commercial intelligence platform for MedTech companies, now available in open beta, that combines medical device data from sales to patient outcomes to track the performance of their products, reimbursement dynamics, target physicians and facilities, and map market shares.
The company will use the funds to enhance its agentic AI capabilities and data model as well as scale its growth.
"AI will transform MedTech, but only with the right context, deeply embedded in the workflows where decisions are made. AcuityMD is that context layer, serving the rep in the field, the commercial leader planning territories and the teams launching the next generation of innovation. I'm grateful to the hundreds of customers who have helped shape our platform," Mike Monovoukas, CEO and cofounder of AcuityMD, said in a statement.
"This funding accelerates our shared mission of accelerating adoption of cutting-edge medical technologies."
MARKET SNAPSHOT
In 2024, AcuityMD scored $45 million in Series B funding, two years after securing $31 million in Series A funding.
The company raised $7 million in seed funding in 2021.
Another company in the space is Definitive Healthcare, which focuses on the business side of healthcare. The company offers healthcare commercial intelligence, data and analytics with the aim of helping companies analyze care providers, claims and market trends.
